

CITATION REPORT

List of articles citing

Basal insulin and cardiovascular and other outcomes in dysgl

DOI: 10.1056/nejmoa1203858

New England Journal of Medicine, 2012, 367, 319-28.

Source: <https://exaly.com/paper-pdf/54042286/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1301	The Efficacy of State Fair Employment Practices Commissions. 1969 , 22, 559-567		1
1300	The fats of life in diabetes. 2012 , 12, 216-220		3
1299	Diabetes: basal insulin and n-3 fatty acids--no effect on cardiovascular outcomes. 2012 , 8, 446		1
1298	Frñhe Insulintherapie im Netzwerk individualisierter Therapie des Typ-2-Diabetes. 2012 , 7, 429-433		
1297	Prñvention des Typ-2-Diabetes. 2012 , 7, 51-60		1
1296	Diabetes: normal glucose levels should be the goal. 2012 , 8, 510-2		5
1295	Basal insulin and cardiovascular and other outcomes. <i>New England Journal of Medicine</i> , 2012 , 367, 1761-2; author reply 1763-4	59.2	11
1294	Placing the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial in context. 2012 , 17, 118-120		
1293	Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?. 2012 , 30, 138-150		49
1292	Type 2 diabetes: the evolution of a disease. 2012 , 12, 290-298		2
1291	Humalog (lispro) for type 2 diabetes. 2012 , 12, 1541-50		10
1290	Glargine and cancer: can we now suggest closure?. 2012 , 35, 2426-8		7
1289	Glycaemic control and cardiovascular outcome trials in type 2 diabetes. 2012 , 12, 161-164		1
1288	Insulin therapy and cancer in type 2 diabetes. 2012 , 2012, 240634		14
1287	Diabetes: Does glycemic control reduce cardiovascular event rates?. 2012 , 9, 434		1
1286	Wer macht das Rennen [Glipitin oder Insulin?. 2012 , 6, 18-19		
1285	Optimizing treatment strategies with insulin glargine in Type 2 diabetes. 2012 , 7, 377-393		4

1284	Year in diabetes 2012: The diabetes tsunami. 2012 , 97, 4293-301	62
1283	Learning from ORIGIN. 2012 , 4, 191-2	1
1282	What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. 2012 , 97, 4605-12	67
1281	[Current treatment of type 2 diabetes]. 2012 , 53, 1399-410	8
1280	Investigating metformin for cancer prevention and treatment: the end of the beginning. 2012 , 2, 778-90	392
1279	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 309-18	59.2 659
1278	Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study. 2012 , 11, 152	16
1277	Insulin detemir: a review of its use in the management of diabetes mellitus. 2012 , 72, 2255-87	27
1276	Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results. 2012 , 22, 1007-12	9
1275	5(th) Annual Symposium on Self-Monitoring of Blood Glucose (SMBG) applications and beyond, May 3-5, 2012, Dublin, Ireland. 2012 , 14, 1155-73	2
1274	Insulin and cardiovascular disease: biomarker or association?. 2012 , 55, 3145-51	10
1273	[Antihyperglycemic Treatment Guidelines for diabetes mellitus type 2]. 2012 , 124 Suppl 2, 10-6	2
1272	[Insulin therapy of diabetes]. 2012 , 124 Suppl 2, 17-22	3
1271	Keine Kardioprotektion durch frühe Insulinierung. 2012 , 154, 1-1	
1270	Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE. 2012 , 3, 9	12
1269	Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. 2012 , 7, e49908	7
1268	Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. 2012 , 7, e51814	21
1267	Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. 2012 , 35, 722-9	14

1266	Report of the JDS/JCA Joint Committee on Diabetes and Cancer. 2013 , 4, 81-96	26
1265	Insulin as an early treatment for type 2 diabetes: ORIGIN or end of an old question?. 2013 , 36 Suppl 2, S198-204	4
1264	Personalizing guidelines for diabetes management: twilight or dawn of the expert?. 2013 , 11, 161	18
1263	Predictive power of cell-to-cell variability. 2013 , 1, 131-139	19
1262	Beneficial and detrimental effects of glyceimic control on cardiovascular disease in type 2 diabetes. 2013 , 15, 332	2
1261	Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes. 2013 , 13, 319-28	2
1260	Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. 2013 , 13, 342-9	17
1259	Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes. 2013 , 13, 252-60	35
1258	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2013 , 369, 1317-26	59.2 2459
1257	Herz und Diabetes. 2013 , 9, 380-386	
1256	Kardiovaskuläres Risiko bei Hypoglykämie. 2013 , 9, 19-24	
1255	Glycemic control: a combination of lifestyle management and the use of drugs. 2013 , 2, 1-16	3
1254	Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. 2013 , 33, 621-31	47
1253	Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. 2013 , 50, 587-95	34
1252	Diabetes and cancer: Could vitamin D provide the link?. 2013 , 27, 184-90	6
1251	Latest insights into the risk of cancer in diabetes. 2013 , 4, 225-32	60
1250	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. 2013 , 36, 1779-88	114
1249	The impossible return to the Garden of Eden: the ORIGIN trial and the original sin of early insulin treatment of type 2 diabetes. 2013 , 23, e35-6	

1248	Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. 2013 , 36, 3953-60	24
1247	American Association of Clinical Endocrinologists [Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. 2013 , 19, 1-48	102
1246	Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend?. 2013 , 39, 468-76	16
1245	Pharmacoth�apie du diab�e de type 2. 2013 , 37, S428-S436	1
1244	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). 2013 , 34, 3035-87	1444
1243	Abdominal adiposity largely explains associations between insulin resistance, hyperglycemia and subclinical atherosclerosis: the NEO study. 2013 , 229, 423-9	26
1242	Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer. 2013 , 104, 965-76	56
1241	Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. 2013 , 12, 135	56
1240	Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. 2013 , 12, 131	8
1239	Change in HbA1c over 3 years does not improve the prediction of cardiovascular disease over and above HbA1c measured at a single time point. 2013 , 56, 1004-11	6
1238	Diabetes treatment: recent developments. 2013 , 30, 1031-2	1
1237	Dialogue Plus: Management of cardiovascular risk in hyperglycaemic/diabetic patients at hospital discharge. 2013 , 50, 989-98	2
1236	Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. 2013 , 15, 938-53	159
1235	The Metabolic Syndrome. 2013 ,	6
1234	Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?. 2013 , 15, 387-91	10
1233	Cardiovascular disease and the use of insulin. 2013 , 15, 789-91	1
1232	The future of basal insulin. 2013 , 15, 727-32	16
1231	A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. 2013 , 29, 793-9	5

1230	Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. 2013 , 43, 504-13	77
1229	The path to approval of new drugs for diabetes. 2013 , 12, 195-207	11
1228	Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. 2013 , 23, 808-15	67
1227	Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?. 2013 , 36 Suppl 2, S212-8	33
1226	Rosiglitazone and cardiovascular outcomes: is there a clear answer?. 2013 , 128, 777-9	2
1225	Atualização en insuficiencia cardiaca, trasplante cardiaco, cardiopatãas congñitas y cardiologã clñica. 2013 , 66, 290-297	3
1224	Comments on ORIGIN trial. 2013 , 23, e33-4	
1223	Exogenous hyperinsulinemia and atherosclerosis in type 1 diabetic patients. 2013 , 27, 2-3	2
1222	Pharmacologic management of type 2 diabetes. 2013 , 37 Suppl 1, S61-8	101
1221	[Insulin therapy in type 2 diabetes]. 2013 , 32 Suppl 1, 25-31	1
1220	Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics?. 2013 , 74, 207-10	
1219	PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. 2013 , 62, 1365-72	161
1218	Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. 2013 , 1, 71-8	30
1217	The year in atherothrombosis. 2013 , 62, 1131-43	20
1216	The Prediabetes Detection and Physical Activity Intervention Delivery (PRE-PAID) program. 2013 , 37, 415-9	7
1215	Advances in pharmacologic therapies for type 2 diabetes. 2013 , 15, 302	13
1214	Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive. 2013 , 9, 67-8	30
1213	The links between insulin resistance, diabetes, and cancer. 2013 , 13, 213-22	98

1212	Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. 2013 , 98, 668-77	151
1211	Hyperglycemia and vascular metabolic memory: truth or fiction?. 2013 , 13, 403-10	31
1210	Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. 2013 , 9, 763-75	38
1209	Insulin and atherosclerosis: how are they related?. 2013 , 39, 111-7	37
1208	Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. 2013 , 108, 510-9; quiz 520	82
1207	Insulin resistance: a risk marker for disease and disability in the older person. 2013 , 30, 535-48	38
1206	Treatment with Thiazolidinediones. 2013 , 117-146	
1205	The Metabolic Syndrome and Cancer. 2013 , 55-61	1
1204	Examining the role of insulin in the regulation of cardiovascular health. 2013 , 9, 39-52	9
1203	Diabetes and its comorbidities--where East meets West. 2013 , 9, 537-47	102
1202	Update on heart failure, heart transplant, congenital heart disease, and clinical cardiology. 2013 , 66, 290-7	2
1201	The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. 2013 , 93, 51-98	48
1200	Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus. 2013 , 73, 575-93	29
1199	Revisiting the links between glycaemia, diabetes and cardiovascular disease. 2013 , 56, 686-95	110
1198	The metabolic and mitogenic properties of basal insulin analogues. 2013 , 119, 1-14	25
1197	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. 2013 , CD008143	102
1196	Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. 2013 , 15, 776-85	55
1195	Romanian Journal of Diabetes Nutrition and Metabolic Diseases - 20 Years After. 2013 , 20, 5-9	

1194	Hypoglycaemia in diabetic patients: highly undesirable by cardiologists. 2013 , 34, 3102-5	3
1193	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. 2013 , 34, 3137-44	167
1192	Insulin und GLP-1-basierte Therapien [Eine sinnvolle Kombination?]. 2013 , 11, 262-265	
1191	Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?. 2013 , 41, 93-107	16
1190	Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. 2013 , 125, 21-32	18
1189	How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. 2013 , 36 Suppl 2, S180-9	12
1188	Interpreting adverse signals in diabetes drug development programs. 2013 , 36, 2098-106	20
1187	Response to Comment on: Chakkerla et al. Can New-Onset Diabetes After Kidney Transplant Be Prevented? Diabetes Care 2013;36:1406-1412. 2013 , 36, e183	3
1186	Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C . 2013 , 36, e181	
1185	Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. 2013 , 125, 45-51	15
1184	Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 2013 , 36, 3860-2	59
1183	Barriers and solutions to diabetes management: An Indian perspective. 2013 , 17, 594-601	26
1182	Future of newer basal insulin. 2013 , 17, 249-53	3
1181	Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk. 2013 , 2013, 181240	14
1180	Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. 2013 , 36 Suppl 2, S253-8	38
1179	Insulin therapy and cancer. 2013 , 36 Suppl 2, S240-4	27
1178	Early insulinization to prevent diabetes progression. 2013 , 36 Suppl 2, S190-7	22
1177	Is glucose control important for prevention of cardiovascular disease in diabetes?. 2013 , 36 Suppl 2, S259-63	79

1176	Cardiovascular importance of hyperglycemia and hypoglycemia. 2013 , 36 Suppl 2, S267-71	5
1175	Risikofaktormangement bei KHK. 2013 , 13, 34-42	1
1174	Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). 2013 , 36, 2466-74	35
1173	Characteristics associated with maintenance of mean A1C. 2013 , 36, 2915-22	21
1172	Teaching an old drug new tricks: can paroxetine ease the burden of cardiovascular disease in diabetes?. 2013 , 62, 698-700	6
1171	Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. 2013 , 36, 3517-25	31
1170	External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?. 2013 , 30, 300-8	73
1169	Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. 2013 , 36, 294-301	60
1168	New insulins and insulin therapy. 2013 , 15 Suppl 1, S40-7	1
1167	Diabetes and cancer relationships. 2013 , 5, 378-90	15
1166	Interpretation of Chinese Society of Endocrinology consensus statement on hyperglycemia management target in adult inpatients in China. 2013 , 5, 416-20	6
1165	Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes. 2013 , 5, 268-74	8
1164	Management of the patient with diabetes and coronary artery disease: a contemporary review. 2013 , 9, 387-403	7
1163	Clinical utility of insulin and insulin analogs. 2013 , 5, 67-78	31
1162	Glargine safety, diabetes and cancer. 2013 , 12, 247-63	11
1161	Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. 2013 , 22, 2258-68	69
1160	Association between beta cell function and future glycaemic control in patients with type 2 diabetes. 2013 , 60, 517-523	24
1159	Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes. 2013 , 74, 198-201	5

1158	The Year in Cardiology 2012: focus on cardiovascular disease prevention. 2013 , 34, 314-7	6
1157	Diabetes and cancer--an AACE/ACE consensus statement. 2013 , 19, 675-93	68
1156	[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment; 6. Diabetes and cancer]. 2013 , 102, 869-74	
1155	Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device. 2013 , 5, 471-9	6
1154	Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey. 2013 , 7, 1007-23	26
1153	Cancer and diabetes: new links and new challenges. 2013 , 24, 392-395	
1152	Insulin therapy for pre-hyperglycemic beta-cell endoplasmic reticulum crowding. 2013 , 8, e54351	14
1151	Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. 2013 , 8, e79968	22
1150	Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. 2013 , 8, 333-48	77
1149	Role of insulin in the type 2 diabetes therapy: past, present and future. 2013 , 11, 137-44	17
1148	Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. 2013 , 9, 711-7	8
1147	[Evaluation of the DIABOBHU Observational Study]. 2014 , 155, 903-10	
1146	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. 2014 , 7, 169-83	106
1145	Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. 2014 , 10, 173-88	50
1144	Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. 2014 , 3, 923-43	31
1143	Obesity, Type 2 Diabetes and Beta Cell Failure: An Asian Perspective. 2014 , s1,	4
1142	The Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment. 2014 , 03,	
1141	Diabetes Mellitus and Heart Failure. 2014 , 9, 37-42	18

1140	Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). 2014 , 20, 785-91	22
1139	Advances in managing type 2 diabetes: challenging old paradigms and developing new ones. 2014 , 6, 42	4
1138	Bariatric surgery versus intensive medical therapy for diabetes. <i>New England Journal of Medicine</i> , 2014 , 371, 682	59.2 47
1137	Antihyperglycaemic therapies and cancer risk. 2014 , 11, 371-89	19
1136	Insulin, Other Hypoglycaemic Drugs, and Glucagon. 2014 , 36, 645-657	
1135	Diabetes, impaired fasting glucose, and heart failure: it's not all about the sugar. 2014 , 16, 1153-6	16
1134	Influence of insulin and glargine on outgrowth and number of circulating endothelial progenitor cells in type 2 diabetes patients: a partially double-blind, randomized, three-arm unicenter study. 2014 , 13, 137	12
1133	Restoring Insulin Secretion (RISE): design of studies of β cell preservation in prediabetes and early type 2 diabetes across the life span. 2014 , 37, 780-8	67
1132	2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps. 2014 , 11, 5-10	18
1131	A dysglycaemic effect of statins in diabetes: relevance to clinical practice?. 2014 , 57, 2433-5	16
1130	Première année de suivi des patients diabétiques de type 2 mis sous insuline en vie réelle (étude CREDIT-France). 2014 , 8, 623-629	
1129	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. 2015 , 38, 696-705	114
1128	Cardiovascular impact of drugs used in the treatment of diabetes. 2014 , 5, 245-68	46
1127	Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. 2014 , 37, e221-2	4
1126	Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry. 2014 , 37, 1024-31	52
1125	Sex and gender influences on pharmacological response: an overview. 2014 , 7, 469-85	70
1124	Modern basal insulin analogs: An incomplete story. 2014 , 18, 784-93	3
1123	Insulin analogs and cancer: a note of caution. 2014 , 5, 79	11

1122	Omega-3 index and cardiovascular health. 2014 , 6, 799-814	93
1121	Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial. 2014 , 62, 676-86	13
1120	Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors. 2014 , 126, 172-89	4
1119	Macro- and microvascular outcomes in patients with type 2 diabetes treated with rapid-acting insulin analogues or human regular insulin: a retrospective database analysis. 2014 , 122, 92-9	6
1118	Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. 2014 , 5, 95-123	12
1117	New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). 2014 , 37, 2755-62	226
1116	Diabetes and cancer: epidemiology and potential mechanisms. 2014 , 11, 390-4	36
1115	Unsubstantiated concerns over the safety of use of sulphonylureas and insulin for increased risk of diabetes complications. 2014 , 6, 30-2	3
1114	Early therapy for type 2 diabetes in China. 2014 , 2, 992-1002	42
1113	A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action. 2014 , 34, 291-302	11
1112	Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin. 2014 , 16, 881-4	6
1111	Diabetes therapy and cancer risk: where do we stand when treating patients?. 2014 , 81, 620-8	1
1110	The vexed question of hypoglycaemia and health economics. 2014 , 16, 289-93	1
1109	The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. 2014 , 16, 673-88	76
1108	Humaninsulin oder Analoga in der Insulintherapie. 2014 , 10, 466-471	
1107	Insulintherapie bei Typ-2-Diabetes mellitus. 2014 , 10, 460-465	
1106	Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. 2014 , 37, 3301-8	56
1105	A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. 2014 , 30, 2223-31	15

1104	U300, a novel long-acting insulin formulation. 2014 , 14, 1849-60	23
1103	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management. 2014 , 11, 395-409	11
1102	Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up. 2014 , 14, 162	5
1101	Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease. 2014 , 9, 641-658	1
1100	Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. 2014 , 129, 2567-73	8
1099	A review of cardiovascular outcomes in the treatment of people with type 2 diabetes. 2014 , 5, 385-402	11
1098	ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. 2014 , 11, 133-73	137
1097	Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. 2014 , 126, 190-204	10
1096	Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trials. 2014 , 8, 609-14	22
1095	Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. 2014 , 25, 16-23	24
1094	Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. 2014 , 126, 93-105	15
1093	Typ-2-Diabetes. 2014 , 107-202	
1092	Körpergewichtszunahme bei Typ-2-Diabetes-Patienten nach Insulintherapiebeginn. 2014 , 10, 488-489	
1091	Authors' reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?". 2014 , 12, 561-3	2
1090	Comparative effectiveness research and outcomes of diabetes treatment. 2014 , 311, 2275-6	6
1089	Risk of breast cancer by individual insulin use: an international multicenter study. 2014 , 37, 134-43	15
1088	Identifying and meeting the challenges of insulin therapy in type 2 diabetes. 2014 , 7, 267-82	39
1087	Type 2 diabetes and cardiovascular disease: what next?. 2014 , 21, 109-20	35

1086	Basal insulin analogues in the management of diabetes mellitus: What progress have we made?. 2014 , 30, 104-19	72
1085	Temas de actualidad en cardiologã: riesgo vascular y rehabilitaciã cardiaca. 2014 , 67, 203-210	11
1084	Comment on: "Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results". 2014 , 24, e1	
1083	Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. 2014 , 40, 176-85	51
1082	Insulines lentes aujourd'hui et demain : pour quels besoins non ou mal couverts ?. 2014 , 8, 133-140	2
1081	Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. 2014 , 2, 627-33	54
1080	Lipid and non-lipid cardiovascular risk factors in postmenopausal type 2 diabetic women with and without coronary heart disease. 2014 , 37, 261-8	16
1079	Correspondence: Response to letter to the editor by K Scharf and J Morton. 2014 , 24, 146-7	
1078	SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes). 2014 , 46, 3-5	19
1077	Duration of diabetes and effectiveness of insulin in the management of insulin-naïve Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MODality of Insulin treatment eValuation (MOTIV) registry results. 2014 , 51, 655-61	6
1076	Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel. 2014 , 88, 953-66	13
1075	Update in cardiology: vascular risk and cardiac rehabilitation. 2014 , 67, 203-10	2
1074	Periprocedural glycemic control in patients with diabetes mellitus undergoing coronary angiography with possible percutaneous coronary intervention. 2014 , 113, 1474-80	6
1073	Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study. 2014 , 24, 709-16	20
1072	Guã de prãtica clãnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciã con la European Association for the Study of Diabetes. 2014 , 67, 136.e1-136.e56	8
1071	Cancer biology in diabetes. 2014 , 5, 251-64	20
1070	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. 2014 , 57, 1325-31	39
1069	Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience. 2014 , 16, 241-6	14

1068	Insulin resistance, diabetes, and cardiovascular risk. 2014 , 16, 419	99
1067	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. 2014 , 383, 1068-83	915
1066	The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. 2014 , 30, 11-22	76
1065	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. 2014 , 9, 1223-51	21
1064	Prevention of type 2 diabetes mellitus: is it feasible?. 2014 , 30 Suppl 1, 4-12	27
1063	Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. 2014 , 16, 850-60	32
1062	Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. 2014 , 16, 873-6	75
1061	Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus. 2014 , 16, 541	13
1060	One size does not fit all glycemic targets for type 2 diabetes. 2014 , 5, 134-41	21
1059	[Is there a rationale for early insulin treatment in type 2 diabetes?]. 2014 , 156, 37-40	
1058	Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. 2014 , 40, 391-9	24
1057	Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?. 2014 , 2, 856-8	0
1056	Insuline et vřtu du patient : barriře ou levier ?. 2014 , 8, 423-429	2
1055	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. 2014 , 37, 2647-59	48
1054	Modern technologies for glucose monitoring and insulin replacement. 2014 , 42, 703-706	
1053	Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. 2014 , 130, 1374-82	132
1052	Medical complications of diabetes mellitus. 2014 , 45-68	
1051	Comment on: "Insulin glargine in a Brazilian state: should the government disinvest?". 2014 , 12, 559-60	3

1050	Evolution of insulin: from human to analog. 2014 , 127, S25-38	51
1049	We can change the natural history of type 2 diabetes. 2014 , 37, 2668-76	59
1048	The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. 2014 , 37, 2884-94	122
1047	Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. 2014 , 130, 1579-88	479
1046	Effect of long-chain Ω fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. 2014 , 174, 763-71	90
1045	Le risque de cancer associ \grave{a} ux m \acute{e} dicaments du diab \acute{e} te de type 2 (metformine, sulfonyles et insulines). 2014 , 8, 365-371	1
1044	[Cardiovascular preventive recommendations]. 2014 , 46 Suppl 4, 3-15	4
1043	What are the pharmacotherapy options for treating prediabetes?. 2014 , 15, 2003-18	20
1042	Diabetes and cancer: 5 years into the recent controversy. 2014 , 50, 2119-25	38
1041	The cardiovascular effects of insulin. 2014 , 13, 955-66	13
1040	Metabolic memory: mechanisms and implications for diabetic vasculopathies. 2014 , 57, 845-51	7
1039	[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)]. 2014 , 55, 859-62	1
1038	Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. 2014 , 57, 2030-7	9
1037	[Risk factor management of coronary heart disease : what is evidence-based?]. 2014 , 39, 483-94	
1036	The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. 2014 , 37, 1360-6	67
1035	Cardiovascular risk stratification and management in pre-diabetes. 2014 , 14, 493	36
1034	The evolution of insulin glargine and its continuing contribution to diabetes care. 2014 , 74, 911-27	62
1033	On the potential of acarbose to reduce cardiovascular disease. 2014 , 13, 81	34

1032	Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. 2014 , 12, 76	21
1031	Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. 2014 , 63, 2188-95	153
1030	New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). 2014 , 37, 3235-43	210
1029	Insulin therapy in people with type 2 diabetes: opportunities and challenges?. 2014 , 37, 1499-508	94
1028	Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. 2014 , 28, 553-8	6
1027	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. 2014 , 168, 23-9.e2	46
1026	[Type 2 diabetes mellitus: new treatments]. 2014 , 143, 117-23	2
1025	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. 2014 , 2, 843-51	214
1024	Lessons from SAVOR and EXAMINE: some important answers, but many open questions. 2014 , 28, 430-3	12
1023	Cardiovascular disease in diabetes mellitus: risk factors and medical therapy. 2014 , 43, 25-40	33
1022	Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy. 2014 , 24, 10-7	21
1021	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. 2014 , 174, 458-61	64
1020	Definition of intervention points in prediabetes. 2014 , 2, 667-75	44
1019	Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry. 2014 , 104, 410-9	39
1018	Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. 2014 , 16, 1111-20	81
1017	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. 2014 , 383, 2008-17	167
1016	Factors associated with weight gain in people with type 2 diabetes starting on insulin. 2014 , 37, 2108-13	50
1015	Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?. 2014 , 28, 109-117	8

- 1014 Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. **2014**, 311, 2288-96 115
- 1013 New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?. **2014**, 23, 997-1008 8
- 1012 Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. **2014**, 2, 562-72 37
- 1011 Diabetes and cancer: two diseases with obesity as a common risk factor. **2014**, 16, 97-110 160
- 1010 Thérapeutique des troubles glycémiques. **2014**, 115-188
- 1009 Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs. **2014**, 61, 13-8 6
- 1008 New therapeutic approaches in type 2 diabetes mellitus. **2015**, 145, 485-487
- 1007 Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. **2015**, 31, 537-44 11
- 1006 American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan 2015. **2015**, 21, 1-87 390
- 1005 [Factors limiting glycaemic control in insulin-treated type 2 diabetes]. **2015**, 156, 1443-50
- 1004 Wie kriegt man das Gefäßrisiko in den Griff?. **2015**, 9, 34-45
- 1003 Enzyme replacement and substrate reduction therapy for Gaucher disease. **2015**, CD010324 40
- 1002 Long-Term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. **2015**, 4, 5
- 1001 Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study. **2015**, 14, 106 11
- 1000 Safety of antidiabetes medications: An update. **2015**, 98, 185-95 23
- 999 Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. **2015**, 17, 1194-7 6
- 998 Use and reporting of restricted randomization: a review. **2015**, 21, 1205-11 6
- 997 Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. **2015**, 98, 145-61 23

996	Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill". 2015 , 98, 162-9	11
995	WITHDRAWN: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. 2015 , CD008143	13
994	The prevention of diabetes and cardiovascular disease in people with schizophrenia. 2015 , 132, 86-96	19
993	Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study. 2015 , 17, 1158-65	3
992	Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials. 2015 , 14, 150-3	1
991	Emerging Link between Diabetes and Cancer. 2015 , 16, 170-176	
990	Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. 2015 , 11, 107-16	8
989	Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. 2015 , 11, 569-78	2
988	Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multi-axial approach. 2015 , 6, 1092-6	9
987	Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. 2015 , 10, e0125421	27
986	Cardiovascular effects of basal insulins. 2015 , 7, 113-20	8
985	Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine. 2015 , 2015, 962346	
984	β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. 2015 , 6, 109-24	112
983	Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel. 2015 , 36, 1424-7	3
982	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. 2015 , 36, 2288-96	178
981	New forms of insulin and insulin therapies for the treatment of type 2 diabetes. 2015 , 3, 638-52	61
980	Lipid effects and cardiovascular disease risk associated with glucose-lowering medications. 2015 , 17, 608	2
979	A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. 2015 , 6, 7060	84

978	Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges. 2015 , 17, 607	21
977	50 years forward: mechanisms of hyperglycaemia-driven diabetic complications. 2015 , 58, 1708-14	36
976	High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. 2015 , 8, e002328	41
975	HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. 2015 , 14, 124	21
974	Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden. 2015 , 98, 108-11	1
973	Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis. 2015 , 4, R16-24	28
972	A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues. 2015 , 36, 1040-50	12
971	Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes. 2015 , 39 Suppl 5, S148-54	18
970	Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. 2015 , 5, e006341	14
969	Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. 2015 , 5, e007959	21
968	Causal inference methods to assess safety upper bounds in randomized trials with noncompliance. 2015 , 12, 265-75	
967	Équilibre glycémique et satisfaction de patients diabétiques de type 2 insuffisamment contrôlés au Maroc : résultats après 6 mois de traitement par insuline glargine. 2015 , 9, 695-700	2
966	Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. 2015 , 17, 100	35
965	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. 2015 , 6, 573-591	24
964	Histoire critique des recommandations nutritionnelles : l'exemple des lipides et des maladies cardiovasculaires. 2015 , 50, 6S42-6S49	
963	Comment expliquer la controverse ^propos de l'efficacité/sécurité cardiovasculaire dans les essais cliniques concernant le diabète de type 2 ?. 2015 , 9, 752-758	
962	Weighing the benefits and risks of diabetes drugs: a call for a unified global approach. 2015 , 39, 1-2	1
961	[The association of hyperinsulinemia with cardiovascular risk and cancer poses new challenges in the treatment of the insulin resistance type 2 diabetes patient]. 2015 , 32, 21-6	

960	Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society. 2015 , 215, 117-29	8
959	"Mild dysglycemia" in type 2 diabetes: to be neglected or not?. 2015 , 29, 451-8	16
958	Vascular Complications of Diabetes Mellitus. 2015 , 1541-1593	
957	Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. 2015 , 3, 136-45	190
956	[Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society]. 2015 , 62, e23-36	2
955	New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). 2015 , 17, 386-94	218
954	Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. 2015 , 52, 649-62	72
953	Benefits of timely basal insulin control in patients with type 2 diabetes. 2015 , 29, 295-301	35
952	Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. 2015 , 38, 22-8	55
951	Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. 2015 , 64, 673-86	139
950	Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society. 2015 , 215, 117-129	5
949	Continuous subcutaneous insulin infusion in patients with type 2 diabetes: a cohort study to establish the relationship between glucose control and plasma oxidized low density lipoprotein. 2015 , 9, 573-80	6
948	Insulinothérapie basale: pourquoi des objectifs glycémiqes ambitieux?. 2015 , 9, 3S4-3S8	
947	Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis. 2015 , 9, 326-33	2
946	Hyperglycemia. 2015 , 85-100	
945	Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 2015 , 132, 923-31	281
944	Antidiabetic drugs and risk of cancer. 2015 , 67, 1240-50	14
943	[New therapeutic approaches in type 2 diabetes mellitus]. 2015 , 145, 485-7	

942	PEGylated insulin Lispro (LY2605541): clinical overview of a new long-acting basal insulin analog in the treatment of Type 2 diabetes mellitus. 2015 , 10, 365-374	3
941	Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. 2015 , 10, 381-398	
940	Risk Prediction for Early CKD in Type 2 Diabetes. 2015 , 10, 1371-9	66
939	Does using HbA1c inform diagnosis of diabetes in patients with coronary artery disease?. 2015 , 36, 1149-51	4
938	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. 2015 , 36, 1454-62	83
937	Emerging treatments for post-transplantation diabetes mellitus. 2015 , 11, 465-77	47
936	[Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society]. 2015 , 47, 456-68	3
935	Insulin therapy in insulin resistance: could it be part of a lethal pathway?. 2015 , 240, 400-1	13
934	High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events. 2015 , 240, 318-23	25
933	Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. 2015 , 3, 367-81	63
932	Protocolo sobre manejo de la diabetes mellitus tipo 2. 2015 , 22, 9-40	
931	Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. 2015 , 31, 89-101	3
930	[Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society]. 2015 , 41, 266-78	3
929	Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion. 2015 , 9, 1	
928	A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy. 2015 , 14, 13	6
927	Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/+WAPCre mouse model. 2015 , 17, 14	18
926	Higher glucose, insulin and insulin resistance (HOMA-IR) in childhood predict adverse cardiovascular risk in early adulthood: the Pune Children's Study. 2015 , 58, 1626-36	28
925	Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. 2015 , 108, 350-9	18

924	Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. 2015 , 468, 125-32	103
923	Clinical features and treatment of coronary heart disease in diabetes. 2015 , 1064-1078	1
922	Atherogenesis, coronary heart disease and insulin resistance syndrome in diabetes. 2015 , 1031-1045	
921	Prevention of type 2 diabetes. 2015 , 550-563	
920	Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. 2015 , 41, 183-94	97
919	Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. 2015 , 11, 372-9	20
918	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. 2015 , 3, 356-66	193
917	Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. 2015 , 38, 1339-46	84
916	Identifying prediabetes - Is it beneficial in the long run?. 2015 , 81, 282-6	8
915	[Glucose-lowering therapy in patients with cardiac comorbidities]. 2015 , 140, 650-6	0
914	[Treatment of stable coronary artery disease in type II diabetes mellitus: drugs, coronary intervention and bypass surgery]. 2015 , 140, 657-62	0
913	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. 2015 , 132, 2297-304	49
912	The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. 2015 , 173, 53-61	14
911	New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus. 2015 , 49, 1153-61	28
910	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. 2015 , 132, 691-718	239
909	Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. 2015 , 16, 299-304	6
908	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. 2015 , 38, 1567-82	133
907	Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study. 2015 , 6, 339-55	2

906	Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors. 2015 , 127, 842-54	5
905	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. 2015 , 38, 2000-8	26
904	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. 2015 , 38, 1777-803	271
903	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. 2015 , 38, 1627-33	20
902	Diabetes Mellitus and Colorectal Cancer Risk. 2015 , 11, 209-216	0
901	Sex-specific differences in diabetes prevention: a systematic review and meta-analysis. 2015 , 58, 242-54	30
900	Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus. 2015 , 17, 231-44	9
899	Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. 2015 , 32, 305-13	24
898	Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. 2015 , 17, 350-62	46
897	Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial. 2015 , 29, 134-41	4
896	Concomitant diabetes mellitus and heart failure. 2015 , 40, 7-43	54
895	Practical combination therapy based on pathophysiology of type 2 diabetes. 2016 , 9, 355-369	14
894	rDNA insulin glargine U300 - a critical appraisal. 2016 , 9, 425-441	6
893	Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?. 2016 , 14, 316-8	1
892	Effects of Growth Hormone on Diurnal Insulin Sensitivity in Normal and Type 2 Diabetic Patients and Animal Models. 2016 , 7,	
891	The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. 2016 , 49, 139-48	44
890	The Characteristics of Patients whose both Fasting and Postprandial Glucose were Controlled by Once Daily Basal Insulin Monotherapy. 2016 , 07,	
889	Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS. 2016 , 2016, 1643496	3

888	Individual Fatty Acids in Cardiometabolic Disease. 2016 , 207-318		1
887	Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. 2017 , 9, 19-29		18
886	Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. 2016 , 15, 78		9
885	All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine. 2016 , 11, e0151910		9
884	Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes. 2016 , 33, 1737-1743		3
883	Insulin, insulin receptors, and cancer. 2016 , 39, 1365-1376		124
882	The EMPA-REG outcome study: critical appraisal and potential clinical implications. 2016 , 15, 85		13
881	Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. 2016 , 18, 990-8		39
880	Adaptive Designs for Clinical Trials. <i>New England Journal of Medicine</i> , 2016 , 375, 65-74	59.2	230
879	Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes. 2016 , 34, 86-91		9
878	Advances in Basal Insulin Therapy. 2016 , 32, 260-268		78
877	Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial. 2016 , 6, e008377		9
876	Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues. 2017 , 16, 227-236		14
875	How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016 , 471-492		
874	Ischemic Heart Disease in Diabetes. 2016 , 653-658		
873	Diabetes and Cancer: Evidence for Risk, Methodology and Implications. 2016 , 789-798		
872	Epidemiology of Type 2 Diabetes. 2016 , 43-64		
871	Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter?. 2016 , 19, 394-399		26

870	Are the most recent basal insulins really the most innovative?. 2016 , 147, 297-299	
869	Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care. 2016 , 34, 34-43	4
868	Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. 2016 , 40, 193-5	29
867	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. 2016 , 118, 1830-43	46
866	Author's reply. 2016 , 67, 304	
865	Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture. 2016 , 65, 1462-71	129
864	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. 2016 , 38, 1288-1298	24
863	High Quality of Diabetes Care Based Upon Individualised Treatment Goals - A Cross Sectional Study in 4784 Patients in Germany. 2016 , 124, 294-9	10
862	The metabolic vascular syndrome - guide to an individualized treatment. 2016 , 17, 5-17	25
861	Diabetes Dyslipidemia. 2016 , 7, 203-19	171
860	Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. 2016 , 41, 208-16	3
859	Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin. 2016 , 53, 717-26	6
858	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. 2016 , 39, 717-25	211
857	[Insulin therapy of diabetes]. 2016 , 128 Suppl 2, S54-61	1
856	[Antihyperglycemic treatment guidelines for diabetes mellitus type 2]. 2016 , 128 Suppl 2, S45-53	4
855	Newly detected abnormal glucose regulation and long-term prognosis after acute myocardial infarction: Comparison of an oral glucose tolerance test and glycosylated haemoglobin A1c. 2016 , 214, 310-5	18
854	Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. 2016 , 30, 1177-85	13
853	Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG. 2016 , 38, 1279-1287	15

852	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. 2016 , 17, 117-27	3
851	Insulin glargine use and breast cancer risk: Associations with cumulative exposure. 2016 , 55, 851-8	10
850	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. 2016 , 179, 175-83	51
849	Handbook of Insulin Therapies. 2016 ,	1
848	[Are the most recent basal insulins really the most innovative?]. 2016 , 147, 297-9	
847	Maladie coronarienne et diab�e de type 2 : des liens g�n�tiques. 2016 , 10, 21-22	0
846	Risk factors for cancer development in type 2 diabetes: A retrospective case-control study. 2016 , 16, 785	24
845	[Not Available]. 2016 , 48 Suppl 1, 4-26	5
844	Insulino-s�rtagogues et insulinoth�apie : niveau de preuve et controverses. 2016 , 10, 376-379	
843	Current perspectives on cardiovascular outcome trials in diabetes. 2016 , 15, 139	51
842	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. 2016 , 16, 116	33
841	Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. 2016 , 26, 1071-1078	12
840	Impact of EMPA-REG OUTCOME on the management of type 2 diabetes mellitus: a review for primary care physicians. 2016 , 128, 822-827	
839	Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. 2016 , 39, 1684-92	43
838	Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. 2016 , 18, 152-8	23
837	New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). 2016 , 18, 375-83	58
836	[Comparison of two insulin glargine formulations: biosimilar vs. reference product]. 2016 , 158 Suppl 5, 19-27	1
835	Glycaemic control and cardiovascular disease: is there a light at the end of the tunnel?. 2017 , 110, 421-423	3

834	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. 2016 , 15, 111	40
833	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. 2016 , 39, 1186-201	86
832	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. 2016 , 39, 1915-1924	32
831	Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. 2016 , 12, 1267-1271	7
830	Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. 2016 , 15, 96	6
829	When Ecells fail: lessons from dedifferentiation. 2016 , 18 Suppl 1, 117-22	55
828	Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials. 2016 , 121, 69-85	10
827	Comprehensive therapeutic approach for patients with heart failure and comorbidity. 2016 , 216, 323-330	
826	Personalized Therapy by Phenotype and Genotype. 2016 , 39 Suppl 2, S127-36	11
825	Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes Council. 2016 , 39 Suppl 2, S146-53	17
824	New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?. 2016 , 39 Suppl 2, S172-9	19
823	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. 2016 , 39 Suppl 2, S210-8	17
822	Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. 2016 , 39 Suppl 2, S244-52	134
821	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. 2016 , 39 Suppl 2, S187-95	37
820	Management of postprandial glucose: Recommended targets and treatment with biphasic insulin. 2016 , 10, 391-397	3
819	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. 2016 , 9,	16
818	Dose d'insuline et mortalité cardiovasculaire : nouvelles données de l'étude ACCORD. 2016 , 10, 23-24	
817	Complicaciones macrovasculares de la diabetes. Evaluación del riesgo cardiovascular y objetivos terapéuticos. Estrategias de prevención y tratamiento. 2016 , 12, 947-957	1

816	The impact of insulin resistance on the kidney and vasculature. 2016 , 12, 721-737	151
815	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. 2016 , 134, e535-e578	164
814	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. 2016 , 18, 749-758	6
813	Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice. 2016 , 311, E335-45	6
812	Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. 2016 , 16, 39	29
811	Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism. 2016 , 6, 23320	6
810	Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy. 2016 , 4, e000206	5
809	Hypertension in type 2 diabetes: impact of glucose-lowering medications. 2016 , 5, 137-143	
808	Kardiovaskuläre Effekte von Antidiabetika. 2016 , 12, 150-153	
807	Beta-cell function is associated with carotid intima-media thickness independently of insulin resistance in healthy individuals. 2016 , 34, 685-91	8
806	Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. 2016 , 59, 2018-25	8
805	Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials. 2016 , 2, 12	10
804	Cardiovascular effects of anti-diabetes drugs. 2016 , 15, 1239-57	11
803	[Diabetes mellitus, coronary artery disease and heart disease]. 2016 , 128 Suppl 2, S212-5	4
802	Ronde Tafel Diabeteszorg streeft naar snelle en gerichte toelating van innovatieve behandelwijzen. 2016 , 14, 14-16	
801	Hypoglykämien bei Diabetes. 2016 , 12, 277-290	1
800	Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. 2016 , 7, 188-198	5
799	Nur Metformin bessert Überlebensraten. 2016 , 10, 16-17	

798	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. 2016 , 54, 32-37		1
797	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. 2016 , 17, 1527-38		2
796	Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus. 2016 , 135, 108-26		4
795	Optimizing management of glycaemia. 2016 , 30, 397-411		5
794	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 311-22	59.2	3606
793	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. 2016 , 133, 2459-502		520
792	Kardiovaskuläre Effekte der Insulintherapie. 2016 , 12, 171-177		1
791	SGLT2 inhibitors in the management of type 2 diabetes. 2016 , 53, 364-72		47
790	[Hypoglycemia--simply annoying or dangerous?]. 2016 , 158, 67-70		
789	Diabetes and the heart--the battle is not lost yet!. 2016 , 41, 173-4		
788	Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?. 2016 , 10, 1		
787	Phenotypes of prediabetes and stratification of cardiometabolic risk. 2016 , 4, 789-798		115
786	Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease. 2016 , 30, 41-9		8
785	The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology. 2016 , 67, 802-9		17
784	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. 2016 , 44, 9-20		1
783	[Treatment of type 2 diabetes]. 2016 , 57, 153-65		3
782	Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials. 2016 , 38, 372-386.e6		16
781	Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy. 2016 , 17, 91-101		17

780	DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. 2016 , 26, 273-84	16
779	The past, present, and future of basal insulins. 2016 , 32, 478-96	48
778	New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). 2016 , 18, 366-74	83
777	Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. 2016 , 11, 281-296	
776	Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. 2016 , 7, 187-201	19
775	Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. 2016 , 42, 71-6	42
774	New Insulins, Biosimilars, and Insulin Therapy. 2016 , 18 Suppl 1, S43-55	4
773	[Hypertension and vascular risk: editorial for «Control of the major cardiovascular risk factors for ischemic cardiopathy in secondary prevention in Aragon: COCINA study». Impact of diabetes mellitus and its metabolic control with regards to cardiovascular risk]. 2016 , 33, 4-6	
772	Diabetology and oncology meet in a network model: union is strength. 2016 , 53, 515-24	14
771	Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus. 2016 , 73, 359-66	11
770	Comprehensive therapeutic approach for patients with heart failure and comorbidity. 2016 , 216, 323-30	4
769	Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. 2016 , 315, 1034-45	126
768	Diabetes and Cancer. 2016 , 31, 135-45	12
767	Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005-2011. 2016 , 39, 363-70	90
766	Hypoglycemia in Diabetes Mellitus as a Coronary Artery Disease Risk Factor in Patients at Elevated Vascular Risk. 2016 , 101, 659-68	17
765	Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study. 2016 , 101, 461-9	16
764	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). 2016 , 39, 709-16	48
763	The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. 2016 , 128, 137-44	6

762	Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. 2016 , 202, 291-6	23
761	Approach to diabetes management in patients with CVD. 2016 , 26, 165-79	28
760	Management of Type 2 Diabetes Mellitus. 2016 , 839-853.e2	2
759	Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. 2016 , 17, 212-21	36
758	Incident Type 2 diabetes and the effect of early regression to normoglycaemia in a population with impaired glucose regulation. 2017 , 34, 396-404	13
757	Managing Diabetic Nephropathies in Clinical Practice. 2017 ,	
756	Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. 2017 , 27, 375-377	4
755	Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. 2017 , 33, 985-992	7
754	A causal role for hyperinsulinemia in obesity. 2017 , 232, R173-R183	78
753	Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. 2017 , 7, e013927	91
752	Diabetes: A diabetes mellitus guideline gone wrong - the 2017 ACP update. 2017 , 13, 191-192	1
751	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. 2017 , 16, 387-396	11
750	Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in Korea. 2017 , 8, 346-353	17
749	Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?. 2017 , 317, 1017-1018	65
748	[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased]. 2017 , 58, 293-302	
747	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. 2017 , 5, 391-402	42
746	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. 2017 , 19, 831-841	60
745	Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target!. 2017 , 40, 291-300	19

744	Microvascular complications after metabolic surgery. 2017 , 5, 240-241		1
743	Impact of hyperglycemia on the efficacy of chemotherapy-A systematic review of preclinical studies. 2017 , 113, 235-241		23
742	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 376, 891-2	59.2	49
741	Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. 2017 , 246, 62-67		7
740	Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. 2017 , 241, 302-310		18
739	Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes. 2017 , 26, 1133-1141		8
738	Cardiovascular safety of insulin: Between real-world data and reality. 2017 , 19, 1201-1204		7
737	Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients. 2017 , 15, 220-225		3
736	The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. 2017 , 14, 345-352		2
735	A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. 2017 , 19, 1645-1654 ²¹		
734	The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. 2017 , 43 Suppl 1, 2S20-2S27		41
733	[Cardiovascular Effects of Antidiabetic Therapies]. 2017 , 142, 737-745		1
732	Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. 2017 , 43, 299-313		16
731	Insulin Receptor Isoforms in Physiology and Disease: An Updated View. 2017 , 38, 379-431		168
730	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. 2017 , 40, 813-820		78
729	Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. 2017 , 40, 821-831		48
728	The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease. 2017 , 31, 311-318		7
727	Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. 2017 , 32, 1044-1051		17

726	Novel Diabetes Drugs and the Cardiovascular Specialist. 2017 , 69, 2646-2656	64
725	Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. 2017 , 28, 561-586	22
724	Diabetes Mellitus and Heart Failure. 2017 , 130, S40-S50	77
723	Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. 2017 , 33, 1821-1831	23
722	Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials. 2017 , 42, 1-15	6
721	So Many Antihyperglycemics: How to Choose? A Practical Approach. 2017 , 41, 469-473	3
720	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 723-732	59.2 349
719	Diabetes Mellitus and Heart Failure. 2017 , 120, S37-S47	98
718	Comorbidities in Heart Failure. 2017 , 243, 35-66	21
717	Mechanisms linking empagliflozin to cardiovascular and renal protection. 2017 , 241, 450-456	24
716	Cardiovascular safety of liraglutide for the treatment of type 2 diabetes. 2017 , 16, 627-635	2
715	The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study. 2017 , 14, 295-303	12
714	Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?. 2017 , 19, 1205-1213	39
713	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. 2017 , 17, 21	22
712	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. 2017 , 40, 687-693	34
711	Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study. 2017 , 11, 590-596	4
710	Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction. 2017 , 2, 111-114	1
709	Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. 2017 , 19, 324-327	3

708	Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes. 2017 , 8, 213-217	1
707	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. 2017 , 123, 199-208	35
706	Understanding the impact of hypoglycemia on the cardiovascular system. 2017 , 12, 21-33	18
705	Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus. 2017 , 89, 1195-1204	15
704	Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. 2017 , 40, 280-283	60
703	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. 2017 , 60, 422-434	55
702	Longitudinal associations between marine omega-3 supplement users and coronary heart disease in a UK population-based cohort. 2017 , 7, e017471	6
701	Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. 2017 , 18, 1291-1300	19
700	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. 2018 , 1067, 197-217	35
699	Orale Triple-Therapie Binnvolle Strategie oder nur Verzögerungstaktik?. 2017 , 13, 416-420	
698	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. 2017 , 70, 2171-2185	39
697	Insulin and Its Cardiovascular Effects: What Is the Current Evidence?. 2017 , 17, 120	19
696	Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials. 2017 , 96, e6022	9
695	The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective. 2017 , 40, 970-973	4
694	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. 2017 , 40, 1144-1151	30
693	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. 2017 , 40, 1273-1284	312
692	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. 2017 , 130, 1465.e27-1465.e39	10
691	NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions. 2017 , 19 Suppl 1, 95-106	12

690	Weak bones in diabetes mellitus - an update on pharmaceutical treatment options. 2018 , 70, 1-17	9
689	Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. 2017 , 34, 1876-1896	8
688	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. 2017 , 40, 1121-1127	32
687	Historique des études cardiovasculaires : de l'UGDP aux dernières études. 2017 , 11, 2S15-2S26	7
686	Études LEADER et EMPA-REG OUTCOME : implications en pratique clinique. 2017 , 11, 2S49-2S55	
685	Cardiovascular disease leads to a new algorithm for diabetes treatment. 2017 , 11, 1126-1133	12
684	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. 2017 , 2, 1025-1029	217
683	Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes?. 2017 , 17, 77	5
682	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. 2017 , 132, 137-143	
681	Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. 2017 , 6, 175-186	12
680	Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. 2017 , 177, 1808-1817	158
679	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. 2017 , 31, 399-421	2
678	Antihyperglycemic agents and cardiovascular outcomes: recent insights. 2017 , 32, 642-650	2
677	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. 2017 , 18, 1243-1260	30
676	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. 2017 , 31, 1451-1457	2
675	iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. 2017 , 51, 990-999	7
674	Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study. 2017 , 3, 5	3
673	Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes. 2017 , 77, 1353-1362	11

672	Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy. 2017 , 19, 153-155	1
671	Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. 2017 , 5, 43-52	27
670	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. 2017 , 39, 1012-1025	12
669	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. 2017 , 49, 51-62	13
668	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. 2017 , 19, 43-53	76
667	Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes. 2017 , 11, 263-269	9
666	Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. 2017 , 56, 449-458	11
665	Editorial commentary: Anti-glycemic drugs and heart failure-A new era. 2017 , 27, 152-154	
664	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. 2017 , 33, 366-377	19
663	Management of Overt Diabetic Kidney Disease and Uremia. 2017 , 77-115	
662	Long-term studies of treatments for type 2 diabetes. 2017 , 129, 352-365	8
661	The impact of glucose-lowering medications on cardiovascular disease. 2018 , 7, 13-17	
660	Möglichkeiten und Grenzen der aktuellen Insulintherapie. 2017 , 11, 37-45	
659	Débat entre Bernard Charbonnel et Michel Marre : quelle place pour les sulfamides hypoglycémisants dans le traitement du diabète de type 2 ? 2017 , 11, 537-538	1
658	Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis. 2017 , 6,	6
657	Achterbahnfahrt mit Schreck und Jubel. 2017 , 11, 3-4	
656	[The safety of anti-diabetic drugs in heart failure]. 2017 , 158, 163-171	1
655	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. 2017 , 10, 273-284	16

654	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. 2017 , 2017, 9257930	0
653	Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience. 2017 , 10, 521-532	8
652	Updates on cardiovascular outcome trials in diabetes. 2017 , 16, 128	36
651	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). 2017 , 9, 53	15
650	Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People. 2017 , 102, 2251-2257	9
649	Preventative strategies. 2017 , 20-28	
648	. 2017 , 109, 1-31	16
647	Efficacy and Safety of Insulin Glargine 300 U/mL in North Americans and Non-North Americans with Type 2 Diabetes: A Patient-Level Meta- Analysis of the EDITION 1, 2 and 3 Studies. 2017 , 09,	
646	Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study. 2017 , 8, 66940-66950	2
645	The impact of type 2 diabetes mellitus on prognosis in patients with non-ST elevation myocardial infarction. 2017 , 14, 127-132	1
644	Antidiabetic Drugs as Antihypertensives: New Data on the Horizon. 2017 , 16, 70-78	3
643	Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. 2017 , 9, 699-710	3
642	Astragaloside IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocin-induced diabetic rat model. 2018 , 41, 1078-1088	16
641	Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?. 2018 , 36, 138-147	5
640	EADSG Guidelines: Insulin Therapy in Diabetes. 2018 , 9, 449-492	52
639	Insulin treatment in patients with diabetes and heart failure: defendant on the stand. 2018 , 20, 896-897	2
638	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. 2018 , 81, 189-222	14
637	Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes. 2018 , 9, 501-519	14

636	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. 2018 , 23, 303-323	27
635	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. 2018 , 20, 853-872	264
634	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. 2018 , 20, 888-895	65
633	Möglichkeiten und Grenzen der aktuellen Insulintherapie. 2018 , 15, 55-63	
632	Long-acting insulin analogs and cancer. 2018 , 28, 436-443	19
631	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. 2018 , 137, 1060-1073	20
630	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. 2018 , 32, 213-222	32
629	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. 2018 , 42 Suppl 1, S88-S103	108
628	Beta cell stress in a 4-year follow-up of patients with type 2 diabetes: A longitudinal analysis of the BetaDecline Study. 2018 , 34, e3016	8
627	Glucose-lowering treatment in cardiovascular and peripheral artery disease. 2018 , 39, 86-98	4
626	The Vasculature in Prediabetes. 2018 , 122, 1135-1150	56
625	Insulin Treatment. 2018 , 1-24	
624	Legacy Effect of Intensive Blood Glucose Control on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Very High Risk or Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials. 2018 , 40, 776-788.e3	9
623	Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?. 2018 , 10, 26	20
622	Prediabetes. 2018 , 34, 615-623	31
621	Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes. 2018 , 196, 208-216.e219	
620	New Insulins, Biosimilars, and Insulin Therapy. 2018 , 20, S55-S70	3
619	Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study. 2018 , 20, 1186-1192	3

618	A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. 2018 , 17, 293-302	22
617	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. 2018 , 61, 1503-1516	40
616	Blood Pressure Control and Cardiovascular/Renal Outcomes. 2018 , 47, 175-184	8
615	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. 2018 , 47, 1-32	12
614	Linking type 2 diabetes and gynecological cancer: an introductory overview. 2018 , 56, 1413-1425	15
613	Effect of glucose-lowering therapies on heart failure. 2018 , 15, 282-291	34
612	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. 2018 , 23, 445-459	4
611	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). 2018 , 137, 88-90	19
610	Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. 2018 , 47, 117-135	16
609	Keeping the right track in the treatment of patients with type 2 diabetes. 2018 , 20, 52-54	2
608	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. 2018 , 41, 14-31	263
607	Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes. 2018 , 20, 1089-1095	4
606	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. 2018 , 16, 123-131	
605	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. 2018 , 78, 203-214	5
604	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. 2018 , 17, 83-95	2
603	Precision medicine in the management of type 2 diabetes. 2018 , 6, 891-900	60
602	Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats. 2018 , 7, 739-748	3
601	Management of Diabetes and/or Hyperglycemia in Acute Coronary Syndrome, Acute Stroke, and Acute Heart Failure. 2018 , 632-647	

600	Dyspnoe bei Diabetes und Herzinsuffizienz. 2018 , 14, 36-43	1
599	Treadmill exercise alleviates diabetic cardiomyopathy by suppressing plasminogen activator inhibitor expression and enhancing eNOS in streptozotocin-induced male diabetic rats. 2018 , 7, 553-559	7
598	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. 2018 , 71, 1379-1390	43
597	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. 2018 , 43, 68-110	15
596	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions. 2018 , 20, 238-244	42
595	Modelling incremental benefits on complications rates when targeting lower HbA levels in people with Type 2 diabetes and cardiovascular disease. 2018 , 35, 72-77	16
594	Diabetes and Cancers. 2018 , 113-126	1
593	Safety of diabetes drugs in patients with heart failure. 2018 , 218, 98-107	
592	Prevention of Type 2 Diabetes. 2018 , 17-29	
591	Safety of diabetes drugs in patients with heart failure. 2018 , 218, 98-107	
590	Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. 2018 , 20, 497-507	22
589	Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. 2018 , 34, 1-10	9
588	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. 2018 , 60, 224-228	8
587	Insulin resistance and cardiovascular outcomes in the ORIGIN trial. 2018 , 20, 564-570	6
586	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. 2018 , 199, 170-175	4
585	Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. 2018 , 20, 800-811	5
584	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. 2018 , 47, 97-116	2
583	Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. 2018 , 40, 215-224	116

- 582 Precision Medicine in Obesity and Type 2 Diabetes: The Relevance of Early-Life Exposures. **2018**, 64, 130-141 16
- 581 Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. **2018**, 20, 821-830 5
- 580 Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?. **2018**, 9, 728-730 3
- 579 Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function. **2018**, 38, 92-101 29
- 578 Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. **2018**, 41, 39-48 19
- 577 Thiazolidinedione therapy and breast cancer risk in diabetic women: A systematic review and meta-analysis. **2018**, 34, e2961 14
- 576 Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. **2018**, 18, 13-24 2
- 575 Pharmacological Intervention for the Prevention of Diabetes Mellitus. **2018**, 19, 140
- 574 Echocardiographic feature of diabetic cardiomyopathy: where are we now?. **2018**, 8, 47-56 18
- 573 Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. **2018**, 11, CD003177 89
- 572 Model-based Modified OGTT Insulin Sensitivity Test Design. **2018**, 51, 86-91 2
- 571 Le mēdecin est-il un inghieur, un artisan, ou un artiste ?. **2018**, 12, 232-236
- 570 Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update. **2018**, 65, 611-624
- 569 Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. **2018**, 10, 791-803 9
- 568 Longitudinal trends in HbA1c in diabetes: Stable means can hide meaningful long-term changes. **2018**, 34, e3065 2
- 567 Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. **2018**, 93, 1629-1647 20
- 566 Consensus document of the Spanish Society of Arteriosclerosis (SEA) for the prevention and treatment of cardiovascular disease in type 2 diabetes mellitus. **2018**, 30 Suppl 1, 1-19 2
- 565 Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update. **2018**, 65, 611-624 19

564	Predictors of Glycemic Control in Patients with Type 2 Diabetes: A Subgroup Analysis of the Observational Registry of Basal Insulin Treatment Study in China. 2018 , 20, 825-832	1
563	The Intersection of Diabetes and Cardiovascular Disease-A Focus on New Therapies. 2018 , 5, 160	4
562	The past decade in type 2 diabetes and future challenges. 2018 , 17, 451-459	7
561	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. 2018 , 20, 112	4
560	Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. 2018 , 18, 102	6
559	Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm". 2018 , 78, 1567-1592	1
558	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. 2018 , 138, 2908-2918	48
557	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2018 , 61, 2461-2498	656
556	11th Annual Symposium on Self-Monitoring of Blood Glucose: April 12-14, 2018, Oslo, Norway. 2018 , 20, 857-880	
555	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2018 , 41, 2669-2701	1307
554	Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus. 2018 , 18, 1113-1121	2
553	Prediabetes in youth: an opportunity to make a difference. 2018 , 2, 693-694	
552	The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. 2018 , 72, e13274	5
551	Kardiovaskuläre Erkrankungen bei Diabetes. 2018 , 14, 393-403	1
550	Evidence-Based Management of Diabetes in Older Adults. 2018 , 35, 1065-1078	11
549	Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis. 2018 , 16, 524-527	9
548	Préparations insuliniques au cours de la dernière décennie.. 2018 , 12, 113-127	5
547	Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2). 2018 , 9, 2399-2406	1

546	Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study. 2018 , 6, e000548	6
545	Revisiting the Diabetes-Heart Failure Connection. 2018 , 18, 134	8
544	Re-examining insulin compared to non-insulin therapies for type 2 diabetes: when in the disease trajectory is insulin preferable?. 2018 , 130, 653-659	2
543	Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. 2018 , 123, 886-904	90
542	Treatment of Diabetes in Patients with Heart Failure. 2018 , 20, 97	
541	Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence. 2018 , 38, 739-757	3
540	Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis. 2018 , 57, 1381-1389	2
539	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. 2018 , 41, 1121-1124	34
538	Insulin therapy, weight gain and prognosis. 2018 , 20, 2085-2092	11
537	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). 2018 , 203, 25-29	15
536	Implications of cardiovascular outcome trials with injectable antidiabetic agents. 2018 , 10, 801-803	0
535	Impact of Insulin and Metformin Versus Metformin Alone on β Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. 2018 , 41, 1717-1725	74
534	Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?. 2018 , 41, 1560-1562	5
533	2020 vision - An overview of prospects for diabetes management and prevention in the next decade. 2018 , 143, 101-112	22
532	Blood Glucose Management of Type 2 Diabetes in the Older People. 2018 , 12, 170-174	5
531	Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. 2018 , 18, 53	62
530	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. 2018 , 33, 197-210	2
529	Cardiovascular Disease in Diabetes. 2018 , 219-237	

528	Risk stratification according to insulin type. 2018 , 20, 1497	2
527	Glycemic Targets and Prevention of Chronic Complications. 2018 , 1-31	
526	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. 2018 , 169, 165-174	27
525	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. 2018 , 18, 64	19
524	Activation of insulin receptors and IGF-1 receptors in COLO-205 colon cancer xenografts by insulin and insulin analogue X10 does not enhance growth under normo- or hypoglycaemic conditions. 2018 , 61, 2447-2457	4
523	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 7, CD003177	112
522	Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 7, CD012345	39
521	Varying Effects of Body Mass Index and Mortality in Different Risk Groups. 2018 , 122, 1155-1160	5
520	ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. 2018 , 19 Suppl 27, 115-135	94
519	Diabetes and Cancer. 2018 , 1-34	
518	Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. 2018 , 18, 78	13
517	Insulin therapy for type 2 diabetes - are we there yet? The d-Nav ² story. 2018 , 4, 8	4
516	Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. 2018 , 17, 9	27
515	The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus. 2018 , 14, 955-963	7
514	The treatment of type 2 diabetes in heart failure. 2018 , 35, 123-126	2
513	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. 2018 , 6, 813-822	20
512	Diabetes and the Cardiovascular System. 2018 , 1-29	
511	Endpoints in diabetes cardiovascular outcome trials. 2018 , 391, 2412	5

510	Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways. 2019 , 45, 238-247	27
509	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. 2019 , 21, 3-14	29
508	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. 2019 ,	25
507	Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death. 2019 , 21, 2626-2634	0
506	Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality. 2019 , 131, 376-382	6
505	Diabetes and the Cardiovascular System. 2019 , 1-29	
504	Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. 2019 , 17, 13	3
503	Prediabetes: lifestyle, pharmacotherapy or regulation?. 2019 , 10, 2042018819863020	5
502	The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. 2019 , 21, 1402-1411	103
501	Insulin treatment in heart failure patients: the good, the bad or the ugly?. 2019 , 21, 985-987	
500	Influence of Timing of Insulin Initiation on Long-term Glycemic Control in Japanese Patients with Type 2 Diabetes: A Retrospective Cohort Study. 2019 , 58, 3361-3367	
499	Clinical aspects of heart failure in individuals with diabetes. 2019 , 62, 1529-1538	9
498	Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. 2019 , 215, 178-186	5
497	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. 2019 , 21, 974-984	30
496	Use of Insulin in Outpatient Diabetes Management. 2019 , 541-554	
495	Does diabetes prevention translate into reduced long-term vascular complications of diabetes?. 2019 , 62, 1319-1328	24
494	Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. 2019 , 98, 104-111	7
493	Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. 2019 , 42, 1800-1808	3

492	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. 2019 , 20,	47
491	Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study. 2019 , 66, 971-982	6
490	Freispruch 1. Klasse: Sulfonylharnstoffe und kardiovaskuläre Ereignisse. 2019 , 19, 17-18	
489	Genetic predisposition to type 2 diabetes is associated with severity of coronary artery disease in patients with acute coronary syndromes. 2019 , 18, 131	9
488	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. 2019 , 4, 831-840	42
487	Personalized Management of Type 2 Diabetes. 2019 , 19, 115	3
486	RSSDI consensus recommendations on insulin therapy in the management of diabetes. 2019 , 39, 43-92	3
485	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. 2019 , 132, S13-S20	1
484	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. 2019 , 22, 1402-1409	6
483	Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage. 2019 , 12, 1225-1237	8
482	An update on pharmacotherapies in diabetic dyslipidemia. 2019 , 62, 334-341	11
481	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus. 2019 , 15, 365-373	6
480	Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. 2019 , 74, 1107-1115	91
479	Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. 2019 , 42, 2032-2041	5
478	Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use. 2019 , 35, 470-480	2
477	Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus. 2019 , 25, 1162-1171	1
476	A comprehensive approach to type 2 diabetes mellitus [A recommendation document]. 2019 , 66, 443-458	1
475	Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. 2019 , 11, 80	21

474	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. 2019 , 40, 1447-1467	85
473	Management of diabetes mellitus in patients undergoing liver transplantation. 2019 , 141, 556-573	14
472	Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention. 2019 , 94, 287-308	24
471	Challenges in the management of people with diabetes and cancer. 2019 , 36, 795-802	8
470	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. 2019 , 132, e599-e609	7
469	Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables. 2019 , 41, 352-367	16
468	Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal. 2019 , 13, 2126-2141	5
467	GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis. 2019 , 14, e0217701	6
466	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. 2019 , 140, e294-e324	168
465	Lack of Durable Improvements in β Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. 2019 , 42, 1742-1751	30
464	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. 2019 , 25, 584-619	30
463	Individuals With Prediabetes Display Different Age-Related Pathophysiological Characteristics. 2019 , 104, 2911-2924	8
462	Management of elevated blood glucose in type 2 diabetes. 2019 , 30, 32-35	
461	Physico-chemical stability of co-formulation of PEGylated human amylin with insulin. 2019 , 24, 975-981	7
460	Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care. 2019 , 42, 1136-1146	7
459	BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion. 2019 , 10, 1189-1204	4
458	Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. 2019 , 21 Suppl 2, 19-23	16
457	Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions. 2019 , 32, 431-447	13

456	Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal. 2019 , 13, 1975-1989	2
455	Comparison of primary versus secondary prevention of cardiovascular disease in patients with type2 diabetes: Focus on achievement of ABC goals. 2019 , 13, 1733-1737	4
454	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. 2019 , 21 Suppl 1, 6-16	7
453	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. 2019 , 12, 447-455	9
452	Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins. 2019 , 75-100	
451	Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. 2019 , 21, 1661-1667	14
450	Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?. 2019 , 21 Suppl 2, 24-33	9
449	Heart failure and diabetes: management and open issues. 2019 , 44, 203-209	1
448	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. 2019 , 104, 1520-1574	146
447	Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. 2019 , 18, 30	24
446	[Diabetes mellitus-Definition, classification, diagnosis, screening and prevention (Update 2019)]. 2019 , 131, 6-15	46
445	[Diabetes mellitus, coronary artery disease und heart disease (Update 2019)]. 2019 , 131, 169-173	0
444	[Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)]. 2019 , 131, 27-38	4
443	Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. 2019 , 33, 462-464	3
442	Aim to normalize glucose levels and reduce cardiovascular mortality when managing type 2 diabetes in the elderly. 2019 , 35, 271-277	
441	Impact des nouvelles classes d'antidiabétiques sur le risque cardiovasculaire dans le diabète de type 2. 2019 , 13, 42-49	1
440	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. 2019 , 21, 1502-1505	1
439	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). 2019 , 21, 1437-1444	9

438	Frühe oder kurzzeitige Insulintherapie bei Typ-2-Diabetes: Stellenwert und Risiko-Nutzen-Bilanz im Rahmen individualisierter Therapiekonzepte. 2019 , 14, 45-55	3
437	Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes. 2019 , 37, 211-220	
436	Clinical implications of cardiovascular outcome trials in type 2 diabetes. 2019 , 44, 192-202	3
435	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. 2019 , 21, 1277-1290	43
434	Treatment of diabetes and heart failure: a paradigm shift for cardiologists?. 2019 , 34, 207-212	2
433	PDM-ProValue meets cardiovascular outcome trials in diabetes. 2019 , 18, 10	2
432	High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone. 2019 , 2019, 2376512	9
431	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA) sowie der Deutschen Gesellschaft für Interventionelle Radiologie (DeGIR)]. 2019 , 14, 3258-3266	0
430	Document on a comprehensive approach to type 2 diabetes mellitus. 2019 , 66, 443-458	13
429	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. 2019 , 13, 205-224	
428	Determining the effects of insulin Detemir on endogenous secretion of insulin. 2019 , 2019, 2943-2946	
427	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. 2019 , 124 Suppl 1, S12-S19	8
426	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. 2019 , 127, S105-S113	3
425	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. 2019 , 26, 73-80	39
424	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. 2019 , 20,	7
423	Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. 2019 , 19, 132	3
422	Full Issue PDF. 2019 , 4, I-CXV	
421	Thiazolidinediones: the Forgotten Diabetes Medications. 2019 , 19, 151	87

420	Long-Acting Basal Insulins: A Review of the More Recently Approved Agents. 2019 , 27, 260-266	8
419	Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials. 2019 , 37, 1939-1949	4
418	Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control. 2019 , 21, M20-M24	
417	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. 2019 , 21, 454-466	57
416	Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study. 2019 , 21, 312-320	6
415	The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial. 2019 , 21, 429-433	2
414	A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide. 2019 , 10, 21-33	9
413	Heart Failure in Type 2 Diabetes Mellitus. 2019 , 124, 121-141	210
412	Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. 2019 , 26, 847-854	6
411	Diabetes: the place of new therapies. 2019 , 10, 2042018818807599	6
410	Evidence-based diabetes care for older people with Type 2 diabetes: a critical review. 2019 , 36, 399-413	40
409	Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States. 2019 , 35, e3097	45
408	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. 2019 , 25, 78-86	13
407	Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. 2019 , 42, 142-147	15
406	How do we identify people at high risk of Type 2 diabetes and help prevent the condition from developing?. 2019 , 36, 316-325	4
405	Real-world studies no substitute for RCTs in establishing efficacy. 2019 , 393, 210-211	56
404	With thanks to The Lancet's reviewers in 2018. 2019 , 393, 211	1
403	Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. 2019 , 36, 265-277	17

402	Post-transplant diabetes mellitus in patients with solid organ transplants. 2019 , 15, 172-188	77
401	Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. 2019 , 79, 173-186	13
400	Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. 2019 , 19, 121-127	6
399	Targeting inflammation to reduce ASCVD in type 2 diabetes. 2019 , 33, 1-3	6
398	Management of Diabetes Mellitus. 2019 , 113-177	
397	Cardiovascular outcome trials in type 2 diabetes: A critical analysis. 2019 , 13, 300-305	1
396	Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. 2019 , 8, 231-241	16
395	Effect of insulin on thyroid cell proliferation, tumor cell migration, and potentially related mechanisms. 2019 , 44, 55-70	2
394	The role of adipose tissue in cardiovascular health and disease. 2019 , 16, 83-99	149
393	Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: Data from the FAST-MI 2005 registry. 2019 , 8, 218-230	9
392	Are newer insulin analogues better for people with Type 1 diabetes?. 2020 , 37, 522-531	3
391	Heart failure and diabetes: The confrontation of two major epidemics of the 21st century. 2020 , 220, 135-138	2
390	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. 2020 , 41, 255-323	1360
389	Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries. 2020 , 97, 143-155	15
388	Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes. 2020 , 14, 193-212	5
387	Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes. 2020 , 43, 398-404	11
386	Strategies of Unloading the Failing Heart from Metabolic Stress. 2020 , 133, 290-296	6
385	Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus. 2020 , 22, 521-529	4

384	Novel Biomarkers for Change in Renal Function in People With Dysglycemia. 2020 , 43, 433-439	1
383	Marine-derived n-3 fatty acids therapy for stroke. 2019 , 6, CD012815	4
382	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. 2020 , 16, 65-73	
381	The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study. 2020 , 43, 103-110	3
380	[Primary prevention of coronary heart disease : Evidence-based drug treatment]. 2020 , 45, 39-49	
379	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. 2020 , 38, 377-386	3
378	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. 2020 , 22, 631-639	39
377	Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study. 2020 , 11, 147-159	4
376	CVOTs: What did the endocrinologist learn?. 2020 , 159, 107947	5
375	Is Insulin Therapy Safe?. 2020 , 27, e106-e114	2
374	The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review. 2020 , 11, 2555-2593	8
373	Considerations for Insulin-Treated Type 2 Diabetes Patients During Hospitalization: A Narrative Review of What We Need to Know in the Age of Second-Generation Basal Insulin Analogs. 2020 , 11, 2775-2790 ¹	
372	Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes. 2020 , 16, 441-456	6
371	Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. 2020 , 170, 108478	2
370	Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study. 2020 , 128, 148-156	1
369	Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2. 2020 , 27, 3-22	0
368	Heart failure and diabetes: The confrontation of two major epidemics of the 21st century. 2020 , 220, 135-138	3
367	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. 2021 , 107, 550-555	2

366	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. 2020 , 172, 541-552	26
365	Japanese Clinical Practice Guideline for Diabetes 2019. 2020 , 11, 1020-1076	46
364	Antidiabetic drugs and blood pressure changes. 2020 , 161, 105108	3
363	Japanese Clinical Practice Guideline for Diabetes 2019. 2020 , 11, 165-223	75
362	Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. 2020 , 105,	4
361	Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin. 2020 , 43, 2333-2335	3
360	Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials. 2020 , 10, 12837	1
359	How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?. 2020 , 38, 339-347	4
358	Insulintherapie bei Diabetes mellitus Typ 2: patientenzentriert, rechtzeitig, nutzen-risiko-bilanziert; Standortbestimmung 2019 nach dem ADA/EASD-Konsensus 2018. 2020 , 15, 65-75	
357	Metformin Should Not Be Used to Treat Prediabetes. 2020 , 43, 1983-1987	8
356	Insulin: too much of a good thing is bad. 2020 , 18, 224	26
355	Cardiovascular disease risk and the time to insulin initiation for Medicaid enrollees with type 2 diabetes. 2020 , 22, 100241	1
354	Hyperinsulinaemia and cancer risk: cause and effect?. 2020 , 37, 223	1
353	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. 2020 , 170, 108488	3
352	(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. 2020 , 11, CD005613	8
351	Co-Formulations as the First Injectable in Type 2 Diabetes: A Review of Efficacy, Safety, and Implications in Clinical Practice. 2020 , 26, 139-151	0
350	Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). 2020 , 73, 404.e1-404.e59	2
349	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. 2020 , 43, 1546-1552	38

348	Genetics of diabetes mellitus and diabetes complications. 2020 , 16, 377-390	172
347	Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. 2020 , 41, 2668-2677	33
346	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. 2020 , 8, 418-435	59
345	The obesity paradox in secondary prevention: a weighty intervention or a wait for more evidence?. 2020 , 41, 2678-2680	6
344	Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy. 2020 , 16, 1359-1370	3
343	Hypoglycaemia and cardiac arrhythmias in diabetes. 2020 , 11, 2042018820911803	12
342	Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. 2020 , 11, 1645-1666	12
341	Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin. 2020 , 132, 667-675	
340	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. 2020 , 8, 606-615	37
339	Risk of hypoglycaemia associated with professional, recreational, and traffic-related activities in patients with type 2 diabetes: a cross-sectional study by questionnaire. 2020 , 57, 965-972	
338	Evaluation and Treatment of Prediabetes in Youth. 2020 , 219, 11-22	10
337	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. 2020 , 141, 1360-1370	8
336	Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. 2020 , 9,	16
335	A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer. 2020 , 17,	1
334	Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins. 2020 , 43, 785-792	1
333	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. 2020 , 83, 587-621	3
332	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. 2020 , 43, 2242-2247	4
331	Rethinking the Relationship between Insulin and Cancer. 2020 , 31, 551-560	14

330	Diabetes and Heart Failure: A Marriage of Inconvenience. 2020 , 36, 447-455	2
329	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154'000 Individuals. 2020 , 9, e014686	24
328	Impact on guidelines: The general practitioner point of view. 2020 , 166, 108091	3
327	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. 2020 , 3, CD003177	75
326	Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel. 2020 , 72, 7-13	1
325	Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey. 2020 , 11, 725-734	2
324	Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction. 2020 , 7, 604-615	4
323	The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives. 2020 , 161, 108053	16
322	Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition. 2020 , 12,	7
321	Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. 2021 , 1307, 129-152	13
320	Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus. 2020 , 10, 5746	2
319	Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines. 2020 , 22 Suppl 2, 33-42	3
318	Diabetes: an Overview for Clinical Oncologists. 2020 , 32, 579-590	0
317	Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes. 2020 , 18, 187-199	0
316	Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients. 2020 , 105,	2
315	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. 2021 , 117, 576-584	10
314	Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. 2021 , 45, 186-197.e2	7
313	Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis. 2021 , 15, 227-233	

312	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). 2021 , 231, 137-146	13
311	How Diabetes and Heart Failure Modulate Each Other and Condition Management. 2021 , 37, 595-608	7
310	Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions. 2021 , 20, 155-169	1
309	3. Prevention or Delay of Type 2 Diabetes:. 2021 , 44, S34-S39	49
308	The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study. 2021 , 50, 75-86	4
307	Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies. 2021 , 78, 923-934	3
306	Cardiovascular Medications. 2021 , 597-642	1
305	Diabetes Mellitus. 2021 , 375-390	
304	Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity. 2021 , 171-205	
303	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. 2020 , 11, 612722	2
302	Clinical research of insulin glargine U300 in type 1 diabetes mellitus patients with frequent hypoglycaemia: real-world experience. 2021 , 6, e102-e108	
301	Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk. 2021 , 11, 1430	1
300	Stress hyperglycemia, cardiac glucotoxicity, and critically ill patient outcomes current clinical and pathophysiological evidence. 2021 , 9, e14713	1
299	Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy.	
298	Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. 2021 , 221, 101-108	1
297	Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials. 2021 , 172, 108648	0
296	Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy.	
295	Creating Composite Indices From Continuous Variables for Research: The Geometric Mean. 2021 , 44, e85-e86	0

294	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. 2021 , 16, 1583-1591	5
293	Hypoglycemia in Older People With Type 2 Diabetes: Prevention and Treatment Strategies for Outpatient and Long-Term Care Facility Settings. 2021 , 36, 112-123	1
292	Hypoglycemia in the emergency, is there any effect on endothelial and diastolic functions?. 2021 , 38, 450-459	1
291	A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes. 2021 , 11, 4152	
290	Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. 2020 , 221, 101-101	1
289	Diabetes and Stroke. 2021 , 22, 26-37	
288	Management of LDL-cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real-life evidence of Under-treatment from the EPHEBUS registry. 2021 , 51, e13528	3
287	Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: A nationwide study. 2021 , 12, 1855-1863	2
286	Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy: A nationwide retrospective cohort study. 2021 , 100, e25085	
285	Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis. 2021 , 22, 399-419	0
284	Individuelle Therapieziele für Menschen mit Diabetes. 2021 , 17, 347-360	0
283	Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial. 2021 , 18, 14791641211002475 ¹	
282	Years of potential life lost in pre-diabetes and diabetes mellitus: data from a 40-year follow-up of the Israel study on Glucose intolerance, Obesity and Hypertension. 2021 , 9,	2
281	Insulin Therapy: The Discovery That Shaped a Century. 2021 ,	5
280	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. 2021 , 17, 283-292	1
279	All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis. 2021 , 173, 108688	2
278	Blood glucose, antidiabetic drugs, and risk of stroke. 2021 , 5, 13-20	
277	Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. 2021 ,	4

276	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 384, 1248-1260	59.2	22
275	Insulin's actions on vascular tissues: Physiological effects and pathophysiological contributions to vascular complications of diabetes. 2021 , 52, 101236		7
274	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. 2021 , 20, 92		8
273	Heart failure at the crossroads of cardiology and diabetology. 2021 , 175, 108844		
272	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. 2021 , 181, 631-649		17
271	The impact of diabetes on heart failure development: The cardio-renal-metabolic connection. 2021 , 175, 108831		0
270	Hyperinsulinemia in Obesity, Inflammation, and Cancer. 2021 , 45, 285-311		14
269	Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. 2021 , 12, 670155		10
268	The current schemes of insulin therapy: Pro and contra. 2021 , 175, 108817		3
267	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). 2021 , 6-61		2
266	[Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases]. 2021 , 61, 66-72		
265	Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis. 2021 , 172, 234-248		2
264	Long-Term Impact of Diabetes Mellitus on Initially Conservatively Managed Patients With Severe Aortic Stenosis. 2021 , 85, 1083-1092		3
263	Identification of genes associated with sudden cardiac death: a network- and pathway-based approach. 2021 , 13, 3610-3627		
262	Therapeutic opportunities for pancreatic β cell ER stress in diabetes mellitus. 2021 , 17, 455-467		11
261	Treating heart failure in patients with diabetes: The view of the cardiologist. 2021 , 176, 108852		1
260	Heart failure management; a perspective from diabetes care. 2021 , 176, 108849		1
259	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. 2021 , 23, 75		3

258	Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. 2021 , 44, 1938-1947	4
257	The effects of antidiabetic agents on heart failure. 2021 , 1	0
256	Si l'ère des insulines semi-synthétiques et biosynthétiques nous fait contè. 2021 , 15, 3S32-3S52	0
255	NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trial. 2021 , 35, 107928	1
254	Comparison of the Efficacy and Safety of Atorvastatin 40 mg/EB Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study. 2021 , 43, 1419-1430	0
253	Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences. 2021 , 46, 272-292	0
252	Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis. 2021 , 18, 1090-1096	3
251	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. 2021 , 22, 2113-2125	
250	Fishing for an Association With Sudden Cardiac Death-Reply. 2021 , 181, 1140-1141	
249	Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?. 2021 , 12, 74-81	1
248	Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. 2021 , 31, 2539-2546	4
247	The effects of insulin therapy on mortality in diabetic patients undergoing percutaneous coronary intervention. 2021 , 9, 1294	3
246	Further RISE'ing to the Challenge of Type 2 Diabetes in Youth. 2021 , 44, 1934-1937	1
245	Differential loss of β cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study. 2021 , 178, 108948	0
244	Adapting Medication for Type 2 Diabetes to a Low Carbohydrate Diet. 2021 , 8, 688540	2
243	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. 2021 , 23, 2775-2784	2
242	Cardiovascular outcomes of antidiabetes medications by race/ethnicity: A systematic review and meta-analysis. 2021 , 35, 107980	2
241	Advances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes. 2021 , 50, 457-474	

240	Basal insulin analogues in people with diabetes and chronic kidney disease. 2021 , e14679	
239	Management of type 2 diabetes without insulin: An update for the PCP. 2021 , 101290	
238	The ongoing evolution of basal insulin therapy over 100 years and its promise for the future. 2021 ,	0
237	Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs. 2021 , 18, 477-497	0
236	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. 2021 , 21, 41	0
235	Praktische Umsetzung einer Insulintherapie bei Typ-2-Diabetes. 2021 , 19, 204-212	
234	Association of Cardiovascular Outcomes and Mortality With Sustained Long-Acting Insulin Only vs Long-Acting Plus Short-Acting Insulin Treatment. 2021 , 4, e2126605	2
233	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. 2021 , 17, e618-e630	0
232	Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy. 2021 , 228, 107920	4
231	Relation between Baseline Coronary Atherosclerotic Status, Cardiovascular Events, and Malignancies in Type 2 Diabetics: A Long-Term Prospective Cohort Study. 2021 , 146, 419-425	2
230	Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 11, CD012345	23
229	Methods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles. 2015 , 3-43	3
228	[New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus]. 2019 , 36, 145-161	3
227	Abordaje integral del paciente con diabetes mellitus tipo 2 y enfermedad cardiovascular o de muy alto riesgo cardiovascular. 2019 , 54, 183-192	5
226	The limitations of observation studies for decision making regarding drugs efficacy and safety. 2019 , 74, 181-185	20
225	ESVM Guideline on peripheral arterial disease. 2019 , 48, 1-79	46
224	5 Conservative treatment for PAD - Risk factor management. 2019 , 48, 1-12	6
223	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft ff.Angiologie (DGA), der Deutschen Gesellschaft ff.Interventionelle Radiologie und minimalinvasive Therapie (DeGIR) sowie der Deutschen Gesellschaft ff.Gefäßchirurgie und Gefäßmedizin (DGG). 2020 , 15, S196-S205	0

222	Diabetes management in older people: a focus on cardiovascular risk reduction. 2017 , 129, 169-177	2
221	Cardiac Sex Differences are Established Prior to Gonad Formation.	3
220	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. 2018 , 20, 42-49	121
219	Drugs for type 2 diabetes: role in the regulation of bone metabolism. 2015 , 12, 130-4	15
218	277. 2013 , 229-277	1
217	Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai. 2013 , 8, e53411	22
216	Efficacy of intensive control of glucose in stroke prevention: a meta-analysis of data from 59,197 participants in 9 randomized controlled trials. 2013 , 8, e54465	17
215	Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts. 2013 , 8, e79710	26
214	Cancer specific mortality in insulin-treated type 2 diabetes patients. 2014 , 9, e93132	14
213	Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. 2014 , 9, e109433	4
212	The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes. 2014 , 9, e109506	31
211	Diabetes, prediabetes and the survival of nasopharyngeal carcinoma: a study of 5,860 patients. 2014 , 9, e111073	5
210	Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. 2016 , 11, e0153594	18
209	Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials). 2016 , 19, 221-228	3
208	Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus. 2016 , 19, 494-510	11
207	Cardiovascular risk in type 2 diabetes patients. 2018 , 17, 81-94	3
206	Obesity, Diabetes and Gastrointestinal Malignancy: The role of Metformin and other Anti-diabetic Therapy. 2018 , 5, 008-14	7
205	Type 2 Diabetes Prevention: Implications of Hemoglobin A1c Genetics. 2015 , 12, 351-62	7

204	A 7.0-7.7% value for glycated haemoglobin is better than a . 2019 , 7, S122	1
203	Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. 2020 , 27, 1089-1131	15
202	Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?. 2020 , 18, 148-157	4
201	Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship?. 2019 , 15, 55-63	42
200	Review of Associations Between Type 2 Diabetes and Cancer. 2020 , 38, 256-265	3
199	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. 2020 , 43, 835-842	16
198	Editorial: Heart Failure in Type 2 Diabetes – The Forgotten Complication. 2018 , 25, 123-130	3
197	Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. 2017 , 21, 1-218	31
196	The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. 2014 , 63, S93-118	106
195	The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. 2020 , 11, 541699	2
194	Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment. 2019 , 43, 733-743	33
193	A low-carbohydrate survey: Evidence for sustainable metabolic syndrome reversal. 2016 , 1,	2
192	Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks. 2020 , 26, 818-829	0
191	Sulfonylurea Glimpiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes. 2015 , 05, 211-226	7
190	Glargine-300: An updated literature review on randomized controlled trials and real-world studies. 2020 , 11, 100-114	7
189	Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. 2014 , 68, 313-6	3
188	A Retrospective Observational Study of Insulin Glargine in Type 2 Diabetic Patients with Advanced Chronic Kidney Disease. 2019 , 11, e6191	2
187	Preventing type 2 diabetes mellitus: a call for personalized intervention. 2013 , 17, 74-9	15

186	Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. 2021 , 22,	6
185	Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. 2021 , 20, 202	3
184	An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus. 2021 , 1-13	1
183	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. 2021 , 398, 1811-1824	35
182	Cardiac proteomics reveals sex chromosome-dependent differences between males and females that arise prior to gonad formation. 2021 , 56, 3019-3034.e7	10
181	Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. 2022 , 65, 206-215	2
180	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG). 2021 , 16, S351-S361	0
179	[Early insulin therapy in type 2 diabetes?]. 2012 , 132, 2151-2	1
178	[Intensive insulin therapy in type 2 diabetes mellitus]. 2012 , 153, 1487-93	
177	Diabetische Entgleisung im Alter. 2013 , 411-431	
176	Vascular Complications of Diabetes Mellitus. 2014 , 1-65	
175	Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes. 2014 , 10, 117-123	0
174	Leitlinien, Betreuungsprogramme, Versorgungsforschung und Evaluation. 2014 , 33-55	
173	Erkrankungen des Stoffwechsels * *Bearbeitet und aktualisiert von Dr. Walter Burghardt. 2014 , 271-380	
172	Diabetische Nephropathie. 2014 , 1-8	
171	Diabetes Mellitus. 2014 , 1-21	
170	[Timely commencement of insulin in type 2 diabetes: benefits and risks]. 2014 , 155, 255-61	
169	Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect. 2014 , 17, 99-107	

- 168 Progressive <i></i></i> Cell Failure in Type 2 Diabetes Mellitus: Microvascular Pancreatic Isletopathy?. **2015**, 05, 21-27 3
- 167 Modern basal insulins: an ongoing story or the start of a new era?. **2015**, 18, 5-11
- 166 Insulin Management in Type 2 Diabetes. **2016**, 83-131
- 165 Insulin resistance - the body's defence against caloric intoxication?. **2016**, 136, 1015-7 0
- 164 Diabetes Mellitus. **2017**, 1649-1668
- 163 Type 2 diabetes therapeutic strategies: why don't we see the «ELEPHANT» in the room?. **2016**, 19, 341-349 3
- 162 Diabetes type 2 diabetes in the elderly </i>olved and unsolved questions. **2016**, 19, 322-330 2
- 161 Evaluation of efficacy of treatment of patients with diabetes mellitus type 2 with the use of different treatment schemes. **2017**, 98, 564-571
- 160 Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. **2017**, 21, 618-629 2
- 159 Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes. **2017**, 18, 7
- 158 Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm. **2017**, 63, 87-92
- 157 DIABETES AND HEART FAILURE. **2017**, 6, 2852-2855
- 156 Advances in insulin therapy. **2017**, 19, 66-71
- 155 Protective Effect of Anti-diabetic Drugs on Cardiovascular Diseases. **2017**, 106, 1029-1036
- 154 Diab&e de type 2 : les m&dicaments hypoglychiants et leurs risques cardiovasculaires. **2017**, 201, 1209-1225
- 153 A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES. **2017**, 38-43 1
- 152 Insulin Treatment. **2018**, 617-640 1
- 151 Diabetes and Cancer. **2018**, 377-410 1

- 150 Enfoque terapéutico de la diabetes mellitus tipo 2 en adultos. Más allá de una meta glucémica. **2018**, 37, 36-46 0
- 149 Glycemic Targets and Prevention of Chronic Complications. **2018**, 421-450
- 148 Using Continuous Glucose Monitoring for Patients with Fasting Hyperglycemia. **2018**, 129-141
- 147 Diabetes and the Cardiovascular System. **2018**, 131-159
- 146 A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018). **2018**, 64, 405-426
- 145 Diabète et insuffisance cardiaque : données épidémiologiques et implications thérapeutiques.. **2018**, 202, 909-917 0
- 144 What should interventional cardiologists do for patients with prediabetes?. **2018**, 14, e968-e970
- 143 Update on Management of Type 2 Diabetes for Cardiologists. **2018**, 14, 273-280 6
- 142 Heart failure in diabetes: From an increased risk to a treatment target. **2018**, 21, 399-403 1
- 141 Diabetes and Cardiovascular Disease. **2019**, 709-730
- 140 Diabetes and Cancer. **2019**, 1-34
- 139 Clasificación de los desenlaces en los ensayos clínicos. **2019**, 38, 147-157 0
- 138 Thérapeutique des troubles glycémiés. **2019**, 141-252
- 137 Diabetes and the Cardiovascular System. **2019**, 1-29
- 136 Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence. **2018**, 21, 524-533 1
- 135 ANALOGHI DELL'INSULINA E CANCRO. **2019**, 31, 12-21
- 134 Heart failure and diabetes mellitus: insight into comorbidity. **2019**, 22, 79-87 1
- 133 Bezüglich der kardiovaskulären Ereignisse bekam der Sulfonylharnstoff einen Freispruch 1. Klasse. **2019**, 13, 43-45

- 132 Pharmacotherapy of Diabetes Focused on Stroke. **2019**, 37, 235-250
- 131 Continuous glucose monitoring - proved hypoglycemia in sodium-glucose co-transporter-2 inhibitors - treated type 2 diabetes patients: a link to ketosis development. **2019**, 1, 52-69
- 130 Type 2 diabetes and cancer: problems and suggestions for best patient management. **2020**, 1, 184-204 4
- 129 Insulin Centennial: Milestones influencing the development of insulin preparations since 1922. **2021**, 0
- 128 Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation. **2020**, 44, 785-801
- 127 Heart Failure in Diabetes Mellitus: An Updated Review. **2020**, 26, 5933-5952 1
- 126 Molecular mechanisms underlying effects of n ω and n ω -3 fatty acids in cardiovascular diseases. **2020**, 427-453 3
- 125 Prevention of Type 2 Diabetes. **2020**, 2, 63
- 124 Vascular Complications in Type 2 Diabetes. **2020**, 509-525
- 123 Diabetes and Cancer. **2020**, 377-410
- 122 Diabetes and the Cardiovascular System. **2020**, 131-159
- 121 Treatment of Diabetes and Heart Failure. **2020**, 719-733
- 120 Insulin Therapy. **2021**, 117-129 0
- 119 β Prediabetes a Risk Factor or Is It a Disease? **2021**, 1-16
- 118 Diabetes and cardiovascular disease: what have we learned in 2012?. **2013**, 40, 290-2
- 117 Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. **2014**, 18, 617-23 6
- 116 Diabetic oncopathy--one more yet another deadly diabetic complication!. **2014**, 140, 15-8 2
- 115 DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety. **2015**, 5, 471-8 12

114	Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?. 2018 , 71, 282-285	
113	Cardiovascular outcomes and safety with antidiabetic drugs. 2018 , 12, 70-83	5
112	The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. 2018 , 2,	3
111	Effects and mechanisms of glucose-insulin-potassium on post-procedural myocardial injury after percutaneous coronary intervention. 2020 , 17, 554-560	
110	Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article.. 2021 , 13, e19398	0
109	Diabetes and Cancer: Risk, Challenges, Management and Outcomes. 2021 , 13,	6
108	Relationship between the early initiation of insulin treatment and diabetic complications in patients newly diagnosed with type 2 diabetes mellitus in Korea: A nationwide cohort study. 2021 ,	
107	Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study. 2021 , 20, 222	0
106	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. 2021 , 1	3
105	Evolution of Glycemic Targets in Management of Diabetes. 2021 , 11, 208-220	
104	Herzinsuffizienz als Komorbidität: Kardioprotektion ist möglich.	
103	Glycaemic Control in Diabetes. 2021 , 47	
102	Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function. 2021 ,	
101	100 Jahre Insulin: Das Hormon des Lebens.	
100	Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.. 2021 , e14780	1
99	The odds of neoplasia in dogs with and without diabetes mellitus.. 2022 ,	1
98	Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.. 2022 , 108132	0
97	Historical Review of the Diagnosis of Prediabetes/Intermediate Hyperglycemia: Case for the International Criteria.. 2022 , 109219	1

96	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.. 2022 , 15, 281-295	7
95	The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms.. 2022 , 13, 800995	2
94	New long-acting insulin analogs: from clamp studies to clinical practice. 2015 , 38, 541-3	15
93	Kommentar zu Diabetes-Subtypen unterscheiden sich in Bezug auf Komplikationen. 2022 , 17, 31-32	
92	Identification of Risk Factors for Coronary Artery Disease in Asymptomatic Patients with Type 2 Diabetes Mellitus.. 2022 , 11,	0
91	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.. 2022 ,	9
90	Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies.. 2022 , 1	
89	Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.. 2022 ,	0
88	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction.. 2022 , 8, e10	
87	Development of clinical prediction models for renal and cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease using time-varying predictors.. 2022 , 108180	
86	CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome.. 2022 , 13, 848310	0
85	Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake.. 2022 , 38, 110509	
84	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. 2022 , 21, 50	1
83	Protective Effects of Eicosapentaenoic Acid on the Glomerular Endothelium via Inhibition of EndMT in Diabetes.. 2021 , 2021, 2182225	0
82	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study.. 2021 , 20, 241	3
81	3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022.. 2022 , 45, S39-S45	8
80	Pharmacotherapy of diabetes mellitus in patients with heart failure - a nation-wide analysis of contemporary treatment.. 2021 ,	0
79	Diabetes and Cancer. 2022 , 443-450	

78	Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia- Data from the ORIGIN Trial.. 2022 ,	
77	Table_1.docx. 2020 ,	
76	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus.. 2022 ,	
75	Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. 2014 , 18, 617	7
74	The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review.. 2022 ,	
73	Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomisation study.	
72	Diabetes mellitus and multiple myeloma; common features of two distinct entities.. 2022 , e3535	0
71	Impact of insulin therapy on outcomes of diabetic patients with heart failure: A systematic review and meta-analysis.. 2022 , 19, 14791641221093175	1
70	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management.. 2022 , 21, 74	1
69	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. 2022 , 18, 402-411	
68	Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).	1
67	The Association of Long-Acting Insulin Analogue Use Versus Neutral Protamine Hagedorn Insulin Use With Major Adverse Cardiovascular Events Among Individuals With Type 2 Diabetes: A Population-Based Cohort Study.	1
66	Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—choice determined by metabolic phenotype.	3
65	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.	0
64	Marine-derived n-3 fatty acids therapy for stroke. 2022 , 2022,	
63	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. 2022 , 37, 415-429	0
62	Long-acting Insulin Analogues. 2022 , 194-213	
61	Positionspapier Herzinsuffizienz und Diabetes.	0

60 Positionspapier Herzinsuffizienz und Diabetes.

59 Effect of Sarcopenia on Mortality in Type 2 Diabetes: A Long-Term Follow-Up Propensity Score-Matched Diabetes Cohort Study. **2022**, 11, 4424 0

58 Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.

57 Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. 5

56 Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial. **2022**, 12, e054100

55 WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. **2022**, 8

54 Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis. **2022**, 21,

53 Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. **2022**, 11, 4660 0

52 A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes. **2022**, 21, 1

51 Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease. **2022**, 359, 1-12 0

50 Herz und Diabetes. **2022**, 1-14 0

49 Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 12

48 Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 16

47 Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen

46 The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial. **2022**, 13, 0

45 Sodium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI). **2022**, 110141 0

44 Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. 0

43 Pharmacotherapy of type 2 diabetes: An update and future directions. **2022**, 137, 155332 3

42	Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study.	0
41	Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.	0
40	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. 2022 , 18, 40-53	0
39	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease: Current Evidence. 2022 , 27, 107424842211463	1
38	Post-Transplant Diabetes Mellitus. 2022 , 391-401	0
37	Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes.	0
36	ISPAD Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes. 2022 , 23, 1277-1296	0
35	Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. 2022 ,	0
34	Physical Activity Changes and the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: A Nationwide Longitudinal Follow-up Cohort Study of 1.8 Million Subjects.	0
33	Are U-shaped relationships between risk factors and outcomes artifactual?. 2022 , 14, 815-821	0
32	" Type 2 Diabetes: Contemporary Challenges " Clinical Pharmacology of Antidiabetic Drugs: what can be expected of their use?. 2022 , 104158	0
31	3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes 2023. 2023 , 46, S41-S48	3
30	Caring for Patients With Diabetes in Stroke Neurology.	0
29	Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases. CJN.05080422	0
28	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. 2023 , 67-138	0
27	Baseline and longitudinal trajectories of body-mass index and all-cause mortality among patients with type 2 diabetes. 2023 , 101426	0
26	Control of Blood Glucose and Cardiovascular Risk Profile. 2023 , 451-469	0
25	Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials. 2023 , 25, 564-569	0

- 24 Au-delà des insulines actuelles : des réalisations prometteuses et quelques déceptions. **2022**, 12, 2868 ○
- 23 Revert diabetes. **2023**, 2, 5 ○
- 22 Atrial Fibrillation and Diabetes Mellitus: Dangerous Liaisons or Innocent Bystanders?. **2023**, 12, 2868 ○
- 21 Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. **2023**, 12, 2868 ○
- 20 Exercise and inactivity as modifiers of β-cell function and type 2 diabetes risk. **2023**, 134, 823-839 ○
- 19 Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP -1) receptor agonists and the glucose-dependent insulinotropic polypeptide/ GLP -1 receptor agonist tirzepatide. **2023**, 25, 1961-1971 ○
- 18 Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial. **2023**, 134, 823-839 1
- 17 Thyroid Dysfunction and Cardiovascular Events in Patients With Dysglycemia. **2023**, 47, 257-262 ○
- 16 Two-year trends from the LANDMARC study: A 3-year, pan-India, prospective, longitudinal study on the management and real-world outcome in patients with type 2 diabetes mellitus. **2023**, 6, 188-197 ○
- 15 Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus. **2023**, 22, 117-126 ○
- 14 Should Type 2 Diabetes Management Be More of a Priority in Post-Acute Coronary Syndrome Patients?. **2023**, 31-38 ○
- 13 The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes. **2023**, 22, 117-126 ○
- 12 Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes. **2023**, 14, 188-197 ○
- 11 Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. **2023**, 22, 117-126 ○
- 10 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167 ○
- 9 Diabetes and Cancer. **2023**, 24, 12-17 ○
- 8 Diabetes: evolution of multifactorial vascular risk reduction. **2023**, 311-335 ○
- 7 Look in or book in: The case for type 2 diabetes remission to prevent diabetic retinopathy. **2023**, 6, 188-197 ○

- 6 Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. **2023**, 8,
- 5 Risk of heart failure in patients with type 2 diabetes receiving insulin therapy: a meta-analysis of observational studies. **2023**, 28, 5375
- 4 Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. **2023**, 13, 1024
- 3 Risk of non-hypoglycemic agents for hypoglycemia-related hospitalization in patients with type 2 diabetes: a large-scale medical receipt database analysis. **2023**, 11, e003177
- 2 Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023). **2023**, 135, 7-17
- 1 Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023). **2023**, 135, 201-206